Descripción del proyecto
La tecnología de «fotocopiado» del ADN agiliza el desarrollo de vacunas
La pandemia de COVID-19 ha puesto de manifiesto la necesidad urgente de desarrollar vacunas. Para mejorar la eficacia y la rapidez del diseño de vacunas, el equipo del proyecto financiado con fondos europeos BIOCOPY ha desarrollado una técnica patentada que puede mejorar significativamente los procesos de desarrollo a un coste menor. La técnica utiliza una superficie recubierta de ADN para generar otras biomoléculas (ADN, ARN o proteínas) que pueden funcionar como objetivos de los patógenos y aprovecharse para el desarrollo de vacunas. Al ser un método que ofrece un alto rendimiento, garantiza el análisis de cientos de proteínas al mismo tiempo, lo que permite obtener resultados rápidamente.
Objetivo
"BioCopy is a spin-off company borned in the University of Freiburg. We have developed an innovative, patented technique to copy biomolecules analogous to a photocopier. A DNA-coated surface is used as copy template. By supplying different biochemical ""copy mixes"", either a DNA, a RNA or a protein copy is generated. After the copy process, the copied biomolecules can be analyzed label-free for their specific binding to target molecules and recovered as potential candidates for a future use as therapeutics or diagnostics. The BioCopy technology completely opens up new dimensions for drug development, vaccines, antibodies, enzymes, catalysts, bioactive coatings, and biosensors and it has are more than 40 future applications. We plan to offer 3 products and services to pharma and biotech companies, related with high- output and cheaper molecular biology screenings. The most promising line is the tailor-made discovery of vaccine candidates within two days. This will have a disruptive character, because the first generation of a vaccine is a billion-dollar market, projected to rise $60 billion on 2019, with 11% growth per annum, and to $100 billion by 2025. BioCopy will provide vaccine candidates to pharmaceuticals, obtaining revenues through upfront, milestone and royalty payments, and they will be responsible for the vaccine´s clinical development, approval and distribution. The multi-awarded BioCopy team covers business know-how and expertise in biology, physics, manufacturing systems engineering, assay development and microsystems technology. BioCopy aims to contribute to the European challenges related with advanced biotechnology applications in pharma sector, and to increase the technological transfer from the academic world into the manufacturing sector. During phase 1 we will build up a detailed business plan and a feasibility study, describing all the needed activities in order to reach BioCopy commercialization. We will need about €2.5M in phase 2."
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesgeneticsRNA
- natural sciencesbiological sciencesmolecular biology
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
79312 EMMENDINGEN
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.